March 6, 2006 -- Cortex Pharma reported positive results for its adult ADHD drug, sending its shares 33% higher; Schering-Plough will continue a trial of its AIDS drug candidate, even though 5 cases of cancer developed among patients; Icagen announced enrollment has passed the halfway point in a Phase III trial of a therapy for sickle cell disease; Wex Pharma of Canada got whacked after its cancer pain drug failed a Phase III trial; Novartis signed a cancer drug development deal with privately held Infinity Pharma that is worth up to $400 million; Centocor said a Phase III trial showed Remicade was effective in treating patients with severe psoriasis; ZLB Behring released post-approval data from a Phase III study showing the effectiveness of Vivaglobin; and Immtech set up a Special Protocol Assessment with the FDA, establishing the design of a Phase III trial for its pneumonia drug. The Centient Biotech 200™ was off by 36 points at 3986.79, a decline of .89%. More details...
